Clinical Policy: Carfilzomib (Kyprolis)
Reference Number: CP.PHAR.309
Effective Date: 02.01.17
Last Review Date: 11.18
Line of Business: Commercial, Medicaid, HIM-Medical Benefit

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Carfilzomib (Kyprolis®) is a proteasome inhibitor.

FDA Approved Indication(s)
Kyprolis is indicated:
- In combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (MM) who have received one to three lines of therapy.
- As a single agent for the treatment of patients with relapsed or refractory MM who have received one or more lines of therapy.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Kyprolis is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Multiple Myeloma (must meet all):
      1. Diagnosis of MM;
      2. Prescribed by or in consultation with an oncologist;
      3. Age ≥ 18 years;
      4. Kyprolis is prescribed in one of the following ways (a, b, or c):
         a. As single agent subsequent therapy;
         b. As combination subsequent therapy with Farydak®, or dexamethasone with or without Pomalyst®;
         c. As primary or subsequent combination therapy with dexamethasone and either Revlimid® or cyclophosphamide;
      *Prior authorization may be required for Farydak, Pomalyst and Revlimid.
      5. Request meets one of the following (a or b):
         a. Dose does not exceed 27 mg/m² for eighteen 28-day cycles;
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration: 6 months
B. Waldenstrom’s Macroglobulinemia (Lymphoplasmacytic Lymphoma) (off-label) (must meet all):
1. Diagnosis of Waldenstrom’s macroglobulinemia (i.e., lymphoplasmacytic lymphoma) (WM/LPL);
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Prescribed as a component of CaRD (carfilzomib, Rituxan® [rituximab], and dexamethasone) regimen as primary or Kyprolis-relapsed therapy;
   *Prior authorization may be required for Rituxan.
5. Request meets one of the following (a or b):
   c. Dose does not exceed 27 mg/m² for eighteen 28-day cycles;
   d. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration: 6 months

C. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. All Indications in Section I (must meet all):
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Kyprolis for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):
   a. New dose does not exceed 27 mg/m² for eighteen 28-day cycles;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies –
IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
- CaRD: carfilzomib, rituximab, dexamethasone
- WM/LPL: Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma
- FDA: Food and Drug Administration
- MM: multiple myeloma
- NCCN: National Comprehensive Cancer Network

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Farydak (panobinostat)</td>
<td>MM: Kyprolis in combination with Farydak, or dexamethasone +/- Pomalyst:</td>
<td>Varies</td>
</tr>
<tr>
<td>Pomalyst (pomalidomide)</td>
<td>• Regimens vary</td>
<td></td>
</tr>
<tr>
<td>Revlimid (lenalidomide)</td>
<td>Kyprolis in combination with dexamethasone and either Revlimid or cyclophosphamide:</td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide Dexamethasone</td>
<td>• Regimens vary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darzalex® (daratumumab)</td>
<td>MM: Examples of primary and subsequent therapy regimens:</td>
<td>Varies</td>
</tr>
<tr>
<td>Empliciti® (elotuzumab)</td>
<td>• Bendamustine</td>
<td></td>
</tr>
<tr>
<td>Kyprolis (carfilzomib)</td>
<td>• Bortezomib/doxorubicin/dexamethasone</td>
<td></td>
</tr>
<tr>
<td>Ninlaro® (ixazomib)</td>
<td>• Bortezomib/thalidomide/dexamethasone</td>
<td></td>
</tr>
<tr>
<td>Revlimid (lenalidomide)</td>
<td>• Bortezomib/lenalidomide/dexamethasone</td>
<td></td>
</tr>
<tr>
<td>Thalomid® (thalidomide)</td>
<td>• Bortezomib/cyclophosphamide/dexamethasone</td>
<td></td>
</tr>
<tr>
<td>Velcade® (bortezomib)</td>
<td>• Carfilzomib/lenalidomide/dexamethasone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Carfilzomib/cyclophosphamide/dexamethasone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Daratumumab/lenalidomide/dexamethasone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/bortezomib</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Elotuzumab/lenalidomide/dexamethasone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ixazomib/lenalidomide/dexamethasone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Lenalidomide/dexamethasone</td>
<td></td>
</tr>
<tr>
<td>Rituxan (rituximab)</td>
<td>WM/LPL: CaRD (carfilzomib, rituximab, and dexamethasone)</td>
<td>Varies</td>
</tr>
</tbody>
</table>
### Table: Dosing Regimen and Dose Limit/Maximum Dose

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyprolis (carfilzomib) dexamethasone</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

**Appendix C: Contraindications/Black Box Warnings**

None reported

### V. Dosage and Administration

#### MM

**Kyprolis with Revlimid and dexamethasone:**
- **Cycles:** Kyprolis IV as a 10-minute infusion for eighteen 28-day cycles.
  - A cycle includes: Kyprolis on Days 1 and 2 of each week for 3 weeks then 12 days off = 28 days.
  - Beginning Cycle 13, omit Kyprolis on Days 8 and 9 of each cycle.
  - Discontinue Kyprolis after Cycle 18.
- **Dose:**
  - Starting dose of Kyprolis: 20 mg/m².
  - If tolerated, escalate Kyprolis to 27 mg/m² on Day 8 of Cycle 1.
  - Revlimid: 25 mg PO QD on Days 1–21 of each cycle.
  - Dexamethasone: 40 mg PO or IV on Days 1, 8, 15, and 22 of each 28-day cycle.

**Kyprolis in combination with dexamethasone:**
- **Cycles:** Kyprolis IV as a 30-minute infusion for eighteen 28-day cycles.
- **Dose:**
  - Starting dose of Kyprolis 20 mg/m².
  - If tolerated, escalate Kyprolis to 56 mg/m² on Day 8 of Cycle 1.
  - Dexamethasone: 20 mg PO or IV on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle.

*Calculate the Kyprolis dose using the patient’s actual body surface area at baseline. In patients with a body surface area greater than 2.2 m², calculate the dose based upon a body surface area of 2.2 m².*

#### VI. Product Availability

Single-dose vial: 30 mg
VII. References

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9047</td>
<td>Injection, carfilzomib, 1 mg</td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy split from CP.PHAR.182 Excellus Oncology.</td>
<td>01.01.17</td>
<td>02.17</td>
</tr>
<tr>
<td>Age and dosing added Safety information removed.</td>
<td>09.05.17</td>
<td>11.17</td>
</tr>
<tr>
<td>NCCN recommended uses added separately.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4Q 2018 annual review: HIM-Medical added; NCCN and FDA-approved uses</td>
<td>08.07.18</td>
<td>11.18</td>
</tr>
<tr>
<td>summarized for improved clarity; specialist involvement in care and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>continuation of care added; MM prior therapy regimens consolidated into</td>
<td></td>
<td></td>
</tr>
<tr>
<td>primary or subsequent therapy; dexamethasone and cyclophosphamide added</td>
<td></td>
<td></td>
</tr>
<tr>
<td>as an MM regimen; references reviewed and updated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Added Commercial line of business to policy.</td>
<td>10.08.19</td>
<td></td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health
plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed,